Smith & Nephew SNATS, Inc. (NYSE:SNN) has earned a consensus recommendation of “Hold” from the seven brokerages that are currently covering the stock, Marketbeat reports. Five investment analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $42.00.
Several analysts have recently issued reports on the company. Morgan Stanley downgraded Smith & Nephew SNATS from an “overweight” rating to an “equal weight” rating in a research note on Monday. Canaccord Genuity assumed coverage on Smith & Nephew SNATS in a research note on Wednesday, October 11th. They set a “buy” rating and a $42.00 price target for the company. Finally, Zacks Investment Research downgraded Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a research note on Tuesday, September 19th.
Several hedge funds have recently made changes to their positions in SNN. Morgan Stanley lifted its position in shares of Smith & Nephew SNATS by 83.9% in the 1st quarter. Morgan Stanley now owns 122,149 shares of the medical equipment provider’s stock worth $3,777,000 after acquiring an additional 55,720 shares during the period. Bank of Montreal Can raised its holdings in shares of Smith & Nephew SNATS by 2.4% in the 2nd quarter. Bank of Montreal Can now owns 23,873 shares of the medical equipment provider’s stock worth $831,000 after buying an additional 558 shares in the last quarter. Wetherby Asset Management Inc. raised its holdings in shares of Smith & Nephew SNATS by 2.6% in the 2nd quarter. Wetherby Asset Management Inc. now owns 16,415 shares of the medical equipment provider’s stock worth $572,000 after buying an additional 415 shares in the last quarter. First Trust Advisors LP acquired a new position in shares of Smith & Nephew SNATS in the 2nd quarter worth approximately $327,000. Finally, Wrapmanager Inc. raised its holdings in shares of Smith & Nephew SNATS by 2.1% in the 2nd quarter. Wrapmanager Inc. now owns 10,178 shares of the medical equipment provider’s stock worth $355,000 after buying an additional 207 shares in the last quarter. Institutional investors own 6.63% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Smith & Nephew SNATS, Inc. (SNN) Receives Average Recommendation of “Hold” from Brokerages” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/11/smith-nephew-snats-inc-snn-receives-average-recommendation-of-hold-from-brokerages.html.
About Smith & Nephew SNATS
Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.
Receive News & Ratings for Smith & Nephew SNATS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew SNATS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.